Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
NCT02439320
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
2231
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Migraine
Interventions
DRUG:
Lasmiditan 100 mg
DRUG:
Lasmiditan 200 mg
DRUG:
Placebo (matches lasmiditan doses)
Sponsor
Eli Lilly and Company
Collaborators
[object Object]